In this interview, SmallCapPower speaks with James Nathanielsz, the CEO of Propanc Bipharma, which is a clinical-stage biopharmaceutical company developing a new treatment for metastatic cancer. Propanc Bippharma’s cancer therapy uses proenzymes from the pancreas to halt the ability of cancer cells to spread and recur. This new frontier in cancer therapy is targeted for patients suffering from pancreatic, ovarian and colorectal cancers. According to James Nathanielsz, an added benefit of their treatment is that it doesn’t cause the typical side effects of standard treatments like nausea, hair loss or a suppressed immune system.
Propanc Biopharma is testing life altering cancer treatment
In this interview, SmallCapPower speaks with James Nathanielsz, the CEO of Propanc Bipharma, which is a clinical-stage biopharmaceutical company developing a new treatment for metastatic cancer. Propanc Bippharma’s cancer therapy uses proenzymes from the pancreas to halt the ability of cancer cells to spread and recur. This new frontier in cancer therapy is targeted for patients suffering from pancreatic, ovarian and colorectal cancers. According to James Nathanielsz, an added benefit of their treatment is that it doesn’t cause the typical side effects of standard treatments like nausea, hair loss or a suppressed immune system.
0 Comments